Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
NCT00002084 · View on ClinicalTrials.gov ↗
Study Summary
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.
Conditions Studied
Interventions
- DRUG Acyclovir
- DRUG Valacyclovir hydrochloride
Study Locations (20)
California
- Combat Group — Los Angeles
- Los Angeles County - USC Med Ctr — Los Angeles
- Infectious Disease Med Group / Adult Immunology Clinic — Oakland
- UCI Med Ctr — Orange
- UCSD Med Ctr — San Diego
- San Diego Naval Hosp — San Diego
- ViRx Inc — San Francisco
- UCSF - San Francisco Gen Hosp — San Francisco
- Dr Marcus Conant — San Francisco
District of Columbia
- Georgetown Univ Med Ctr — Washington D.C.
- Whitman - Walker Clinic — Washington D.C.
- George Washington Univ Med Ctr — Washington D.C.
- Veterans Administration Med Ctr / Regional AIDS Program — Washington D.C.
Georgia
- Emory Univ School of Medicine — Atlanta
- AIDS Research Consortium of Atlanta — Atlanta
Alabama
- Univ of South Alabama — Mobile
Arizona
- Univ of Arizona / Health Science Ctr — Tucson
Connecticut
- West Haven Veterans Administration Med Ctr — West Haven
Florida
- Univ of South Florida — St. Petersburg
Illinois
- Northwestern Memorial Hosp — Chicago
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002084
The ClinicalTrials.gov registry entry for NCT00002084 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 18 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions — of which Acyclovir is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00002084 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, District of Columbia, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00002084 about?
NCT00002084 is a clinical study titled "A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients". To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.
What is the current status of trial NCT00002084?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002084 study?
This clinical trial studies the following conditions: HIV Infections, Herpes Simplex. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00002084?
The interventions under investigation include: Acyclovir (DRUG), Valacyclovir hydrochloride (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00002084?
This trial is sponsored by Glaxo Wellcome, which has 18 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00002084 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.